DocMorris Forecast, price target & analysts
DocMorris Target price 2025 - Analyst rating & recommendation
DocMorris Classifications & Recommendation:
DocMorris Price Target
| Target Price | CHF34.55 |
| Price | CHF17.91 |
| Potential |
92.88%
register free of charge
|
| Number of Estimates | 11 |
|
11 Analysts have issued a price target DocMorris 2026 .
The average DocMorris target price is CHF34.55.
This is
92.88%
register free of charge
CHF60.00
235.01%
register free of charge
CHF17.00
5.08%
register free of charge
|
|
| A rating was issued by 12 analysts: 4 Analysts recommend DocMorris to buy, 8 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the DocMorris stock has an average upside potential 2026 of
92.88%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2028
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Billion CHF | 1.02 | 1.20 |
| 4.91% | 18.48% | |
| EBITDA Margin | -4.52% | -2.05% |
| 35.16% | 54.62% | |
| Net Margin | -9.59% | -5.98% |
| 19.26% | 37.63% |
13 Analysts have issued a sales forecast DocMorris 2025 . The average DocMorris sales estimate is
This results in the following potential growth metrics:
12 Analysts have issued an DocMorris EBITDA forecast 2025. The average DocMorris EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
10 DocMorris Analysts have issued a net profit forecast 2025. The average DocMorris net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2028
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share CHF | -8.25 | -6.10 |
| 15.30% | 26.06% | |
| P/E | negative | |
| EV/Sales | 0.36 |
10 Analysts have issued a DocMorris forecast for earnings per share. The average DocMorris EPS is
This results in the following potential growth metrics and future valuations:
Current DocMorris Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| BERENBERG |
Locked
➜
Locked
|
Locked | Jan 02 2025 |
| HSBC |
Locked
➜
Locked
|
Locked | Nov 24 2024 |
| HAUCK AUFHAEUSER INVESTMENT BANKING |
Locked
➜
Locked
|
Locked | Oct 29 2024 |
| RESEARCH PARTNERS AG |
Locked
➜
Locked
|
Locked | Oct 16 2024 |
| BAADER HELVEA EQUITY RESEARCH |
Locked
➜
Locked
|
Locked | Oct 14 2024 |
| WARBURG RESEARCH GMBH |
Locked
➜
Locked
|
Locked | Oct 14 2024 |
| STIFEL EUROPE |
Locked
➜
Locked
|
Locked | Oct 14 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
BERENBERG:
Locked
➜
Locked
|
Jan 02 2025 |
|
Locked
HSBC:
Locked
➜
Locked
|
Nov 24 2024 |
|
Locked
HAUCK AUFHAEUSER INVESTMENT BANKING:
Locked
➜
Locked
|
Oct 29 2024 |
|
Locked
RESEARCH PARTNERS AG:
Locked
➜
Locked
|
Oct 16 2024 |
|
Locked
BAADER HELVEA EQUITY RESEARCH:
Locked
➜
Locked
|
Oct 14 2024 |
|
Locked
WARBURG RESEARCH GMBH:
Locked
➜
Locked
|
Oct 14 2024 |
|
Locked
STIFEL EUROPE:
Locked
➜
Locked
|
Oct 14 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
